Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 3/20 | 0.45 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18496714 | 0.88 | FOLH1 (0.64) | FOLH1 | |
| SCHEMBL18516883 | 0.88 | FOLH1 (0.64) | FOLH1 | |
| SCHEMBL18516882 | 0.88 | FOLH1 (0.64) | FOLH1 | |
| SCHEMBL1564794 | 0.87 | ALDH1A1 (0.45) | NOD1FOLH1ALBGNPATEPHX2 | |
| SCHEMBL30003706 | 0.86 | GLP1R (0.42) | NOD1GLP1R | |
| SCHEMBL22994976 | 0.84 | MEN1 (0.51) | NOD1FOLH1 | |
| SCHEMBL867922 | 0.84 | CAPN1 (0.47) | FOLH1ALB | |
| SCHEMBL867921 | 0.84 | CAPN1 (0.47) | FOLH1ALB | |
| SCHEMBL19358763 | 0.84 | MEN1 (0.51) | NOD1FOLH1 | |
| SCHEMBL19358764 | 0.84 | MEN1 (0.51) | NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | NOD1 744/4885FOLH1 1591/4885ALB 2369/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | NOD1 744/4885FOLH1 1591/4885ALB 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.